Basic Information
AirNexis Therapeutics is a clinical-stage biotechnology company dedicated to developing novel therapeutic drugs for the treatment of patients with COPD. AN01 is a dual PDE3/4 inhibitor that exerts synergistic effects through a dual mechanism of action, promoting bronchodilation and reducing the release of inflammatory factors.
AirNexis Therapeutics, Inc.
California,United States of America
unclear
January 01, 2025
--